Our study molecularly identifies a key role of SLAMF7 in cholesterol metabolism and trafficking between HCC cells and macrophages and gives a rationale for targeting IL-7 signaling as an effective strategy to sensitize HCC to immunotherapy.

Our results demonstrate that the enhanced colony formation caused by the distinct ANKRD261-1405-RET713-1114 pathomechanism was fully suppressible by RXDX-105/agerafenib and BLU-667/pralsetinib treatments but the increased cell proliferation responded merely moderately. This may suggest that the ANKRD261-1405-RET713-1114-intrinsic pathomechanisms may not be solely brought about by aberrant RET kinase activity but that putative therapeutic interventions may additionally need to focus on ANKRD26 dysfunctions.

P1, N=12, Active, not recruiting, Abdullah Khan | Recruiting --> Active, not recruiting | N=27 --> 12

P1/2, N=24, Active, not recruiting, Yale University | Recruiting --> Active, not recruiting

Elo treatment significantly increased γδ T cell cytotoxicity and degranulation, and these effects were prevented by Fc receptor blockade or by Fc-deficient Elo, indicating an antibody-dependent cellular cytotoxicity (ADCC) mechanism. Our findings demonstrate for the first time that Elo directly boosts γδ T cell anti-tumor activity against PEL, offering novel preclinical evidence for combining Elo with γδ T cell therapy as a potential treatment strategy for this intractable lymphoma.

P1/2, N=142, Completed, SWOG Cancer Research Network | Active, not recruiting --> Completed

P2, N=67, Completed, Bristol-Myers Squibb | Trial completion date: Nov 2025 --> Feb 2026 | Trial primary completion date: Nov 2025 --> Feb 2026

P2, N=28, Active, not recruiting, Medical College of Wisconsin | Recruiting --> Active, not recruiting | N=53 --> 28 | Trial completion date: Jan 2027 --> Jun 2027 | Trial primary completion date: Jan 2026 --> Apr 2027

P1, N=19, Active, not recruiting, Massachusetts General Hospital | Trial primary completion date: Sep 2025 --> Sep 2026

Elotuzumab in MM appears safe but with a specific adverse events pattern : lower neutropenia, but higher respiratory, gastrointestinal, metabolic, and infectious events. Differences may be influenced by longer treatment and corticosteroid use; therefore, interpretation of outcomes such as hyperglycemia and cataracts requires particular caution.

P2, N=67, Completed, Bristol-Myers Squibb | Active, not recruiting --> Completed

ADCC was assessed by flow cytometry using E (100 μg/mL), rituximab (R, 100 μg/mL), and their combination (E + R). The combination of E + R showed no significant synergy over monotherapies. In conclusion, elotuzumab induced significant ADCC in CLL cells, warranting further therapeutic evaluation.